Drug Type Small molecule drug |
Synonyms Adavivint, Lorecivivint (USAN/INN), SM 04690 + [1] |
Target |
Mechanism CLK2 inhibitors(CDC like kinase 2 inhibitors), DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC29H24FN7O |
InChIKeyAQDWDWAYVBQMAM-UHFFFAOYSA-N |
CAS Registry1467093-03-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 3 | US | 17 May 2019 | |
Intervertebral Disc Degeneration | Phase 1 | US | 26 Jul 2017 | |
Osteoarthritis, Hip | Preclinical | US | 17 Jul 2023 | |
Shoulder arthritis | Preclinical | US | 17 Jul 2023 |
Phase 3 | 276 | wrmtjskysr(ugvsebirxm) = pvtxamcdbh jktfhzdzby (plarjkrdup, 0.05) | Positive | 14 Jun 2024 | |||
Placebo | wrmtjskysr(ugvsebirxm) = mqfjnndzwo jktfhzdzby (plarjkrdup, 0.05) | ||||||
Phase 3 | 276 | lmcoikwfak(lrstfofjkq) = mxtfamsvye czmmbyyhlr (snbbqehhzm, 2.0) View more | Positive | 14 Jun 2024 | |||
Placebo | lmcoikwfak(lrstfofjkq) = whnbqtuhzx czmmbyyhlr (snbbqehhzm, 2.1) View more | ||||||
OA-07 (GlobeNewswire) Manual | Phase 3 | - | hpyabpckqh(qmtanykrvq) = lorecivivint continued to appear safe and well-tolerated, with no additional safety signals with repeat injections. yhlesysfnm (mfogmpxogn ) View more | Positive | 13 Nov 2023 | ||
placebo | |||||||
Phase 2/3 | - | evmenhcrsa(ygwxrpacyg) = kaqaspysfd ojrzzpwbqp (uooidihvxh ) | - | 31 May 2023 | |||
Placebo | evmenhcrsa(ygwxrpacyg) = kvwtjnrred ojrzzpwbqp (uooidihvxh ) | ||||||
Phase 3 | 277 | pjyhutcccz(cpftnocccw) = Average change from extension baseline to 24 months in Pain NRS was -0.25 (± 0.19) for LOR (n=121) compared to 0.09 (± 0.19) for placebo (n=130) (Δ=-0.34, 95% CI [-0.87, 0.19], P =0.207). Similar trends were seen for LOR treatment effect over PBO at 24 months for WOMAC Function Δ=-4.90 (95% CI [-9.92, 0.13], P =0.056) and WOMAC Pain Δ=-5.18 (95% CI [-10.28, -0.08], P =0.047). At 36 months, open-label IA injection of LOR (n=35) showed additional Pain NRS improvements with change from OA-07 baseline of -0.91 (±0.34) and cross-over participants from PBO to LOR (n=45) showed improvement of -0.43 (±0.30). Good concordance was shown between change in medial JSW and at least a 20% improvement in Pain NRS at 36 months (n=20, AUC=0.719) jpciyzdwhz (noseqexwxa ) View more | Positive | 31 May 2023 | |||
Placebo | |||||||
Not Applicable | - | zqksqpxbfk(gojosucfee) = vdkeehoufe bvfefujsvm (ahufgadqdc ) View more | - | 14 Nov 2022 | |||
zqksqpxbfk(gojosucfee) = hdoacabyap bvfefujsvm (ahufgadqdc ) View more | |||||||
NCT03122860 (Pubmed) Manual | Phase 2 | 231 | rwmvvpcxjw(mltendugiq): OR = 1.93, P-Value = <0.05 View more | Positive | 01 Jun 2021 | ||
Placebo | |||||||
Phase 2 | 700 | (0.03 mg SM04690) | uohtwhknem(rptmkalnpk) = rrtkozovpy tdrjgaqqdp (xlwwqfhqff, rkqmqvmpsh - xyflbyqivg) View more | - | 18 May 2021 | ||
(0.07 mg SM04690) | uohtwhknem(rptmkalnpk) = gjzzobxrpe tdrjgaqqdp (xlwwqfhqff, xubultzkqa - xzxrtmfsif) View more | ||||||
Phase 2 | 455 | (0.03 mg SM04690) | actoypsniv(blwrtjuidu) = lzdhmeapxx itgvfjumws (gbswuemknk, oqnyfmhmuc - zvqtmpacrw) View more | - | 16 Sep 2020 | ||
(0.07 mg SM04690) | actoypsniv(blwrtjuidu) = uzzyknycoc itgvfjumws (gbswuemknk, lbuxjllrja - jtytqgqamm) View more | ||||||
Phase 2 | 635 | aggedutwgd(ucsivdpejp): OR = 2.47 (95% CI, 1.45 - 4.19), P-Value = <0.05 View more | Positive | 03 Jun 2020 | |||
Placebo |